204 related articles for article (PubMed ID: 24521523)
1. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.
Ikeda M; Ohkawa S; Okusaka T; Mitsunaga S; Kobayashi S; Morizane C; Suzuki I; Yamamoto S; Furuse J
Cancer Sci; 2014 Apr; 105(4):455-62. PubMed ID: 24521523
[TBL] [Abstract][Full Text] [Related]
2. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
Zhu AX; Gold PJ; El-Khoueiry AB; Abrams TA; Morikawa H; Ohishi N; Ohtomo T; Philip PA
Clin Cancer Res; 2013 Feb; 19(4):920-8. PubMed ID: 23362325
[TBL] [Abstract][Full Text] [Related]
3. Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
Takai H; Kato A; Kinoshita Y; Ishiguro T; Takai Y; Ohtani Y; Sugimoto M; Suzuki M
Cancer Biol Ther; 2009 May; 8(10):930-8. PubMed ID: 19276671
[TBL] [Abstract][Full Text] [Related]
4. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization.
Nakano K; Ishiguro T; Konishi H; Tanaka M; Sugimoto M; Sugo I; Igawa T; Tsunoda H; Kinoshita Y; Habu K; Orita T; Tsuchiya M; Hattori K; Yamada-Okabe H
Anticancer Drugs; 2010 Nov; 21(10):907-16. PubMed ID: 20847643
[TBL] [Abstract][Full Text] [Related]
5. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.
Nakano K; Orita T; Nezu J; Yoshino T; Ohizumi I; Sugimoto M; Furugaki K; Kinoshita Y; Ishiguro T; Hamakubo T; Kodama T; Aburatani H; Yamada-Okabe H; Tsuchiya M
Biochem Biophys Res Commun; 2009 Jan; 378(2):279-84. PubMed ID: 19022220
[TBL] [Abstract][Full Text] [Related]
6. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Ishiguro T; Sugimoto M; Kinoshita Y; Miyazaki Y; Nakano K; Tsunoda H; Sugo I; Ohizumi I; Aburatani H; Hamakubo T; Kodama T; Tsuchiya M; Yamada-Okabe H
Cancer Res; 2008 Dec; 68(23):9832-8. PubMed ID: 19047163
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma.
Bell MM; Gutsche NT; King AP; Baidoo KE; Kelada OJ; Choyke PL; Escorcia FE
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374953
[TBL] [Abstract][Full Text] [Related]
8. A novel bispecific antibody as an immunotherapeutic agent in hepatocellular carcinoma.
Liu Q; Song Q; Luo C; Wei J; Xu Y; Zhao L; Wang Y
Mol Immunol; 2023 Oct; 162():125-132. PubMed ID: 37677989
[TBL] [Abstract][Full Text] [Related]
9. Glypican-3 antibodies: a new therapeutic target for liver cancer.
Feng M; Ho M
FEBS Lett; 2014 Jan; 588(2):377-82. PubMed ID: 24140348
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.
Simonelli M; Zucali P; Santoro A; Thomas MB; de Braud FG; Borghaei H; Berlin J; Denlinger CS; Noberasco C; Rimassa L; Kim TY; English PA; Abbattista A; Gallo Stampino C; Carpentieri M; Williams JA
Ann Oncol; 2016 Sep; 27(9):1782-7. PubMed ID: 27329247
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
[TBL] [Abstract][Full Text] [Related]
12. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
[TBL] [Abstract][Full Text] [Related]
14. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).
Abou-Alfa GK; Yen CJ; Hsu CH; O'Donoghue J; Beylergil V; Ruan S; Pandit-Taskar N; Gansukh B; Lyashchenko SK; Ma J; Wan P; Shao YY; Lin ZZ; Frenette C; O'Neil B; Schwartz L; Smith-Jones PM; Ohtomo T; Tanaka T; Morikawa H; Maki Y; Ohishi N; Chen YC; Agajanov T; Boisserie F; Di Laurenzio L; Lee R; Larson SM; Cheng AL; Carrasquilo JA
Cancer Chemother Pharmacol; 2017 Feb; 79(2):421-429. PubMed ID: 28120036
[TBL] [Abstract][Full Text] [Related]
15. Time-to-event modelling of effect of codrituzumab on overall survival in patients with hepatocellular carcinoma.
Nakamura M; Xu C; Diack C; Ohishi N; Lee RM; Iida S; Kawanishi T; Ohtomo T; Abou-Alfa GK; Chen YC
Br J Clin Pharmacol; 2018 May; 84(5):944-951. PubMed ID: 29381229
[TBL] [Abstract][Full Text] [Related]
16. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
[TBL] [Abstract][Full Text] [Related]
17. Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC.
Caraballo Galva LD; Jiang X; Hussein MS; Zhang H; Mao R; Brody P; Peng Y; He AR; Kehinde-Ige M; Sadek R; Qiu X; Shi H; He Y
Hepatology; 2022 Aug; 76(2):330-344. PubMed ID: 34897774
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
Shitara K; Satoh T; Iwasa S; Yamaguchi K; Muro K; Komatsu Y; Nishina T; Esaki T; Hasegawa J; Kakurai Y; Kamiyama E; Nakata T; Nakamura K; Sakaki H; Hyodo I
J Immunother Cancer; 2019 Aug; 7(1):219. PubMed ID: 31412935
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.
Choo SP; Chowbay B; Ng QS; Thng CH; Lim C; Hartono S; Koh TS; Huynh H; Poon D; Ang MK; Chang S; Toh HC
Eur J Cancer; 2013 Mar; 49(5):999-1008. PubMed ID: 23265712
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
